90 Y-DOTATOC and nephrotoxicity [1]

European Journal of Nuclear Medicine

Volumn 29, Issue 11, 2002, Pages 1543-

  Otte, Andreas ^a,b   Cybulla, Markus ^a,b   Weiner, Stefan M ^a,b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID 1 PHENYLALANINE 3 TYROSINE OCTREOTIDE Y 90; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TRACER; UNCLASSIFIED DRUG; (DOTA(0) PHE(1) TYR(3))OCTREOTIDE; (DOTA(0)-PHE(1)-TYR(3))OCTREOTIDE; DRUG DERIVATIVE; OCTREOTIDE; RADIOPHARMACEUTICAL AGENT; YTTRIUM;

CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; HUMAN; LETTER; METASTASIS; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; RADIATION DOSE; ANIMAL; CARCINOID; CHRONIC KIDNEY FAILURE; INJURY; INTESTINE TUMOR; KIDNEY; NOTE; RADIATION EXPOSURE;

ANIMALS; CARCINOID TUMOR; HUMANS; INTESTINAL NEOPLASMS; KIDNEY; KIDNEY FAILURE, CHRONIC; OCTREOTIDE; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; YTTRIUM RADIOISOTOPES;

EID: 0037487237     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-002-0935-x     Document Type: Letter

References (7)

1. 90Y-DOTATOC. Eur J Nucl Med 2002; 29:435.
2. Boerman OC, Oyen WJ, Corstens FH. Between the Scylla and Charybdis of peptide radionuclide therapy: Hitting the tumour and saving the kidney. Eur J Nucl Med 2001; 28:1447-1449.
3. Behr TM, Behe M, Kluge G, Gotthardt M, Schipper ML, Gratz S, Arnold R, Becker W, Goldenberg DM. Nephrotoxicity versus anti-tumour efficacy in radiopeptide therapy: Facts and myths about the Scylla and Charybdis. Eur J Nucl Med Mol Imaging 2002; 29:277.
4. Bodei L, Chinol M, Cremonesi M, Paganelli G. Facts and myths about radiopeptide therapy: Scylla, Charybdis and Sibyl. Eur J Nucl Med Mol Imaging 2002; DOI 10.1007/s00259-002-0864-8.
5. 90Y-DOTATOC. Eur J Nucl Med 2001; 28:1552-1554.
6. Otte A, Jermann E, Behe M, Goetze M, Bucher HC, Roser HW, Heppeler A, Mueller-Brand J, Maecke HR. DOTATOC - A powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 1997; 24:792-795.
7. Moulder JE, Fish BL, Cohen EP. Angiotensin II receptor antagonists in the treatment and prevention of radiation nephropathy. Int J Radiat Biol 1998; 73:415-421.